When Arista™ AH is used in conjunction with autologous blood salvage circuits, carefully follow instructions in the Administration section of the IFU regarding proper filtration and cell washing.Īrista™ AH is intended to be used in a dry state.
Safety and effectiveness in neurosurgical and ophthalmic procedures has not been established.Īrista™ AH should not be used for controlling post-partum bleeding or menorrhagia. If signs of infection or abscess develop where Arista™ AH has been applied, re-operation may be necessary in order to allow drainage. Because there have been reports of decreased amylase activity in newborns up to 10 months, absorption rates of Arista™ AH in this population may be longer than 48 hours.Īrista™ AH should be used with caution in the presence of infection or in contaminated areas of the body. Safety and effectiveness of Arista™ AH have not been clinically evaluated in children and pregnant women. The possibility of the product interfering with normal function and/or causing compression necrosis of surrounding tissues due to swelling is reduced by removal of excess dry material. Once hemostasis is achieved, excess Arista™ AH should be removed from the site of application by irrigation and aspiration particularly when used in and around foramina of bone, areas of bony confine, the spinal cord, and/or the optic nerve and chiasm. Arista™ AH swells to its maximum volume immediately upon contact with blood or other fluids.
Arista c 41 full#
0 kommentar(er)
